Connect Biopharma Completes Enrollment of CBP-307 Global Phase 2 Clinical Trial in Moderate-to-Severe Ulcerative Colitis
November 19, 2021 08:00 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO, CA and TAICANG, SUZHOU, China, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage...
Connect Biopharma Reports Positive Top-Line Results from the Global Phase 2 Clinical Trial of CBP-201 in Patients with Moderate-to-Severe Atopic Dermatitis
November 18, 2021 16:02 ET
|
Connect Biopharma Holdings Limited
Primary endpoint met with all three CBP-201 arms achieving significant improvements Significant improvements also reported for key secondary endpoints including other measures of skin clearance and...
Connect Biopharma to Participate at Upcoming Conferences
November 11, 2021 08:00 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO, CA and TAICANG, SUZHOU, China, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage...
Connect Biopharma to Participate at the Jefferies Virtual China Biotech Summit
October 19, 2021 08:00 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO, CA and TAICANG, SUZHOU, China, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage...
Connect Biopharma Announces First Subject Dosed in Phase 2 Trial Evaluating CBP-201 in Adult Patients with Chronic Rhinosinusitis with Nasal Polyps
September 08, 2021 08:00 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO, CA and TAICANG, SUZHOU, China, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage...
Connect Biopharma Announces First Patient Dosed in China Pivotal Trial Evaluating CBP-201 in Adults with Moderate-to-Severe Atopic Dermatitis
September 02, 2021 08:00 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO, CA and TAICANG, SUZHOU, China, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage...
Connect Biopharma Provides Business Update and Reports First Half 2021 Financial Results
August 31, 2021 16:05 ET
|
Connect Biopharma Holdings Limited
- On Track to Report CBP-201 Phase 2B Top-Line Data Evaluating Moderate-to-Severe Atopic Dermatitis (AD) in Q4 of 2021 - - Cash Balance of RMB 2,025.0 Million (USD 313.5 Million) at June 30, 2021 - ...
Connect Biopharma to Host First Half 2021 Financial Results Conference Call on September 1, 2021
August 25, 2021 08:00 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO and TAICANG, SUZHOU, China, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage...
Connect Biopharma Hires General Counsel & Chief Compliance Officer and Appoints a New Board Member
August 23, 2021 16:05 ET
|
Connect Biopharma Holdings Limited
TAICANG, SUZHOU, China and SAN DIEGO, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage...
Connect Biopharma to Participate at the Jefferies Virtual Healthcare Conference
May 26, 2021 08:00 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO and TAICANG, SUZHOU, China, May 26, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage...